Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Oxidative Stress in Diabetic Kidney Transplant Recipients
NCT04918407Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Serum level of superoxide dismutase at 90 days. Started Jan 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04918407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918407.